Virbac agrees to acquire veterinary assets from Eli Lilly in the United States

(Thomson Reuters ONE via COMTEX) -- Virbac agrees to acquire veterinary assets

from Eli Lilly in the United States

Carros, France - October 27th, 2014

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission's review of Eli Lilly's pending acquisition of Novartis Animal Health worldwide.

Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two major parasiticides for dogs: Sentinel(R)Flavor Tabs and Sentinel(R) Spectrum, currently marketed in the United States by Novartis Animal Health.

In the United States, Sentinel Flavor tabs and Sentinel Spectrum are expected to reach total revenues of approximately $90 to $100 million US dollars in 2014. Adding these strong brands and commercial franchise to the current Virbac portfolio of products offered to veterinary clinics and pet owners in the United States will substantially strengthen Virbac's presence and penetration in the U.S. companion animal veterinary market and leverage its growth potential.

The completion of this transaction is subject to approval by the Federal Trade Commission, which Virbac expects may be received in the near future. It is also conditioned on the closing of the acquisition of Novartis Animal Health by Eli Lilly and should occur shortly thereafter.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Virbac via Globenewswire

HUG#1865807

Virbac agrees to acquire veterinary assets from Eli Lilly in the US - http://hugin.info/136717/R/1865807/655275.pdf

Copyright (C) 2014 Thomson Reuters ONE. All rights reserved.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…